F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. F-star is pioneering the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in cancer therapy. The Company has four second-generation immuno-oncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate. F-star has over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS.
Location: United Kingdom, England, Cambridge
Employees: 51-200
Total raised: $46.16M
Founded date: 2006
Investors 6
| Date | Name | Website |
| 08.11.2022 | M Ventures | m-ventures... |
| - | Medison Ve... | medisonven... |
| - | Atlas Vent... | atlasventu... |
| - | Horizon Te... | horizontec... |
| - | MP Healthc... | mp-healthc... |
| - | TVM Capita... | tvm-lifesc... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 23.10.2013 | Series A | $12.95M | - |
| 13.04.2011 | - | $21.69M | - |
| 06.01.2010 | Series A | $11.52M | - |
Mentions in press and media 16
| Date | Title | Description |
| 03.12.2020 | F-star Therapeutics Announces First Patient Dosed in First-in-Class FS120 Phase 1 Clinical Trial | |
| 22.10.2020 | F-star Therapeutics to Present at SITC 2020 Virtual Annual Meeting | |
| 27.02.2019 | Cofinitive shortlisted for International Trade Champion award at Business Weekly Awards | Cofinitive shortlisted for International Trade Champion award at Business Weekly Awards 27-02-2019 Cofinitive is delighted to announce it has been shortlisted among the brightest and best of elite Cambridge-based companies in the upcoming B... |
| 07.06.2018 | F-star Announces Early Exercise by Denali Therapeutics of its Option to Acquire F-star Gamma | Cambridge, UK, 30 May 2018 – F-star, a clinical-stage biopharmaceutical company developing novel bispecific antibodies, announced today that its partner Denali Therapeutics (NASDAQ: DNLI) (Denali) has chosen to exercise early its option to ... |
| 05.06.2017 | F-star expands its relationship with Merck through a new strategic collaboration | F-star, a biopharmaceutical company developing novel bispecific antibodies, announces today a new partnership with Merck, a leading science and technology company, for the development and commercialisation of five bispecific immuno-oncology... |
| 05.06.2017 | F-star expands its relationship with Merck through a new strategic collaboration | F-star expands its relationship with Merck through a new strategic collaboration 05-06-2017 F-star, a biopharmaceutical company developing novel bispecific antibodies, announces today a new partnership with Merck, a leading science and tech... |
| 28.04.2017 | Bristol-Myers passed on its $475M deal to option F-star drug; Zymeworks IPO raises $59M | John Haurum → A little more than two years ago, Bristol-Myers agreed to ante up $50 million to get an option on F-star’s experimental cancer drug for HER-2 positive cancers. But now we learned that the biotech giant is takin... |
| 25.08.2016 | Denali grabs another megaround while inking a flurry of neurodegeneration R&D pacts | South San Francisco-based upstart Denali Therapeutics has been busy. A little more than a year after making a splash with its $217 million startup round designed to fund a new breed of neurodegeneration drug developer, ... |
| 30.10.2014 | TVM Capital Life Science counts two successful biotech IPOs of portfolio in one week; Bristol- Myers Squibb Entered into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. | TVM Capital Life Science counts two successful biotech IPOs of portfolio in one week: Proteon Therapeutics, Inc, Waltham, USA and Probiodrug AG, Halle, Germany. Additionally, Bristol- Myers Squibb Entered into Agreement that Provides an Exc... |
| 23.10.2013 | F-star announces formation of new asset-centric vehicle, F-star Alpha Ltd, with €9.4m Series A investment. | - |
Show more